Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the pharmacokinetics (PK) of a single 3 gm dose of
cefazolin from a DUPLEX container, in adult subjects (weighing >/= 120 kg) scheduled for
surgery. Cefazolin will be administered as a 30-minute intravenous (IV) infusion, per
cefazolin Package Insert. Five PK samples per subject will be obtained up to 8 hours after
dosing. These data will then be assessed by the validated Cefazolin PK Model to verify there
are no significant PK changes within this study population.